Provectus slammed in early trading

Investors lack enthusiasm for shares of Provectus Biopharmaceuticals (PVCT -65.3%) today in apparent response to the FDA's thumbs down regarding its BTD application for PV-10. The agency cites the lack of data demonstrating that PV-10 is substantially better than existing therapies. Shares plummet on a 3x surge in volume.

Despite the setback, the company still plans to commercialize the product.

From other sites
Comments (1)
  • sheeple123jump
    , contributor
    Comments (411) | Send Message
    Provectus share price collapsed earlier this week after a questionable article generated short attack campaign. PVCT management refuted several misleading comments .


    Investors regain enthusiasm,and rally price back through rest of the week.
    Share price held support at .67 today and rallied higher to close the week 150% above the oversold panic crash bottom.


    Short attackers and deceptive article writers appear to continue their smear tactic campaign,in what appears to misrepresent the company's scientific developments, painting a negative bias that serves to benefit the short attackers.
    Potential investors are urged to go to PVCT web site and examine the story for oneself.


    Despite the short attack efforts by evidently misleading bashers, it is believed the company still plans to embrace and move forward within the scope of reality and truthfulness.
    Investors are encouraged to pursue truth and embrace reality as well.


    Caution is advised as PVCT appears to remain the target of short attackers who may not be embracing the concept of truthfullness. Discernment is advised
    31 May 2014, 02:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs